Isocitrate Dehydrogenase Wild-type Glial Tumors, Including Glioblastoma

Hematol Oncol Clin North Am. 2022 Feb;36(1):113-132. doi: 10.1016/j.hoc.2021.08.007. Epub 2021 Oct 30.


Isocitrate dehydrogenase (IDH) 1 and 2 mutations represent essential components for the diagnosis of diffuse astrocytic tumors and oligodendroglioma. IDH wild-type glial tumors include a wide spectrum of tumors with differences in prognosis and recommended therapeutic approaches. Tumors characterized as molecular glioblastoma in the World Health Organization 2021 classification should be treated according to the glioblastoma therapeutic principles and included in glioblastoma trials. Improving on existing treatments options including targeted and immunotherapy approaches is imperative for most patients with IDH wild-type glial tumors, and enrollment in clinical trials is encouraged.

Keywords: Glioblastoma; Glioma; H3K27M mutant glioma; IDH wild-type; Pilocytic astrocytoma; Pleomorphic xanthoastrocytoma.

Publication types

  • Review

MeSH terms

  • Brain Neoplasms* / genetics
  • Brain Neoplasms* / therapy
  • Glioblastoma* / genetics
  • Glioblastoma* / therapy
  • Glioma*
  • Humans
  • Isocitrate Dehydrogenase / genetics
  • Oligodendroglioma*


  • Isocitrate Dehydrogenase